Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience

Table 2 Statistical analysis of the changes in the major biochemical parameters

Parameters	Baseline	End of treatment		SVR12		Univariate analysis
Parameters	Mean ± SD (range)	Mean ± SD (range)	p Value	Mean ± SD (range)	p Value	p Value	η²	Power
Cryocrit, %	1.8 ± 1.3 (0.5–4)	0.4 ± 0.6 (0–2)	<0.0001	0.8 ± 1.4 (0–4.6)	0.001	<0.0001	0.470	0.999
Rheumatoid factor, IU/L	69.3 ± 119.1 (0–530)	30.9 ± 58.8 (0–255)	0.003	40.1 ± 63.0 (0–244)	0.083	0.002	0.281	0.913
C4, mg/dl	9.6 ± 7.3 (0–24)	13.6 ± 8.8 (4–36)	0.003	14.1 ± 9.4 (2–40)	0.002	0.001	0.313	0.962
ALT, IU/L	104.8 ± 144.7 (13–668)	20.9 ± 5.6 (12–32)	<0.0001	21.1 ± 6.6 (8–32)	<0.0001	<0.0001	0.572	1.000

Abbreviations: ALT Alanine transaminase, C4 Complement component C4, SVR12 Sustained virological response 12 weeks after therapy completion

ISSN: 1478-6362